Hepatosplenic T-cell lymphoma (HSTCL) is a rare type of peripheral T-cell lymphoma characterized in young adult males by hepatosplenomegaly, B-symptoms, peripheral blood cytopenias and no lymphadenopathy; lymphomatous infiltrates in the splenic red pulp, hepatic sinusoids and bone marrow sinuses; T cell receptor (TCR) gd-chain and cytotoxic T-cell phenotype; isochromosome (i) 7q in conjunction with other abnormalities, most commonly trisomy 8; and aggressive clinical course. [1] [2] [3] [4] Recently, rarer types of HSTCL with ab T-cell phenotype (HSabTCL) have occasionally been reported. 5 These lymphomas generally show CD4À and CD8 þ phenotype; however, 'double negative' CD4À and CD8À cases are also reported. Natural killer cell-associated antigens such as CD16, CD56 and CD57 are frequently expressed, although not all cases of HSabTCL, including those with CD4À and CD8 þ cytotoxic T-cell phenotype, express granzyme B. Clinical presentation has been reported to be similar to that described previously for HSgdTCL, except for the female preponderance and age distribution -some younger and older patients. 5 Here, we report a patient with HSabTCL whose lymphoma was resistant to high-dose chemotherapy with autologous peripheral blood stem cells (PBSC) rescue, and was successfully treated by allogeneic bone marrow transplantation .
A 26-year-old Japanese male suffering from high-grade fever for a month was referred to Tsukuba University Hospital in December 2002. Physical examination showed hepatosplenomegaly without lymphadenopathy. Laboratory data showed hemoglobin level of 12.2 g/dl, platelet count, 5.7 Â 10 4 /ml, white blood cell count, 4600/ml with normal differentiation; GOT, 89 U/l; glutamate pyruvate transaminase, 191 U/l; lactate dehydrogenase, 584 U/l (normal: o232); bilirubin, 1.7 mg/dl; C-reactive protein, 0.32 mg/dl; and soluble interleukin-2 receptor (sIL-2R) 25 000 U/ml (normal: o519). Neither anti-HTLV-I nor anti-HIV antibodies was detected. Bone marrow aspiration revealed infiltration of abnormal lymphocytes accounting for 28.8% of nucleated cells. They were irregularly shaped, medium to large in size with basophilic and relatively abundant cytoplasm. The nuclear chromatin was loosely condensed with irregular nuclear outlines. Immunophenotype of these lymphocytes was CD2 þ , CD3 þ , CD4À, CD5À, CD7 þ , CD8À, CD10À, CD16 þ , CD19À, CD20À, CD25À, CD30À, CD56 þ , TCRab þ , TCRgdgÀ, and granzyme BÀ. In situ hybridization of Epstein-Barr virus-encoded RNA-1 (EBER-1) was negative. Genomic Southern blot analysis of the bone marrow cells showed clonal rearrangement of TCR b-chain. Cytogenetic analysis showed 47, XY, i(7)(q10), þ 8 karyotype. Computed tomography scanning of the whole body revealed hepatomegaly and giant splenomegaly exceeding the midline of the anterior abdominal wall, but no lymphadenopathy. Collectively, the patient was diagnosed as having HSabTCL, stage IVB, involving into the bone marrow, spleen, and liver. Three courses of dose-escalated cyclophosphamide, doxorubicin, vincristine and prednisone regimen reduced the fever and liver dysfunction; however, splenomegaly persisted. After a course of chemotherapy containing highdose methotrexate, vincristine, adriamycin, cyclophosphamide and prednisolone, he was treated by high-dose chemotherapy regimen with ifosfamide 3 g/m 2 /day, days 1-4 supported by PBSC harvested after the second and third courses of the chemotherapy. PR was achieved with marked regression of splenic size, normalization of sIL-2R (547 U/ml), and no obvious lymphoma involvement in the bone marrow. However, 3 months later, the lymphoma relapsed presenting with fever, leucocytopenia, thrombocytopenia, liver dysfunction, hepatosplenomagaly and bone marrow infiltration. The patient was treated by hyper-CVAD (cyclophosphamide, vincristine, doxorubicin and dexamethasone) chemotherapy and subsequently by two courses of high-dose chemotherapy containing cytarabine (3 g/m 2 Â 2, days 1, 2), which resulted in complete remission. The patient then received allogeneic BMT from an HLA-matched sibling with conditioning regimen of conventional doses of CY and total body irradiation (TBI) and graft-versus-host disease (GVHD) prophylaxis of CsA and short-term MTX. Engraftment was achieved successfully. However, as splenic enlargement was noted again on CT scanning on day 25 after BMT, and 40 Gy of splenic irradiation was added, which resulted in gradual reduction of the spleen. The patient has not experienced acute GVHD or other BMT-related complications. The patient has been in remission for more than 33 months after the allogeneic hematopoietic stem-cell transplantation (HSCT).
Despite a broad array of potential therapeutic approaches, HSgdTCL is an aggressive disease with a median survival of less than 2 years, 3 which is also the case in HSabTCL. 5 Although reported experiences with allogeneic transplantation are limited, demonstration of a graftversus-lymphoma effect would offer potentially curative alternative for patients with HSgdTCL. 4, [6] [7] [8] [9] Thus far, at least three cases of HSgdTCL treated with allogeneic HSCT have been reported: a 23-year-old male, treated with TBI and high-dose etoposide followed by BMT from an HLAmatched sibling in the first remission; 8 a 10-year-old male, treated with CY/TBI followed by matched unrelated HSCT in the second remission; 7 a 25-year-old woman, treated with TBI/thiotepa/CY followed by unrelated-cord blood transplantation to residual disease after autologous PBSC transplantation. 9 All these patients developed mild to moderate acute or chronic GVHDs, which were successfully controlled. Of note, they were all alive and free from relapse despite poor prognosis of the disease at a follow-up period of 23, 12 and 58 months, respectively.
To the best of our knowledge, this is the first report of allogeneic transplantation for HSabTCL. Given that both ab and gdHSTCL possess similar characteristics, we believe that prompt allogeneic HSCT should be considered for this refractory disease, although the data do not provide enough evidence to give a general recommendation. 
